Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shire has filed lawsuits in two US district courts against Andrx Pharmaceuticals for infringement of its patent on Adderall XR for attention deficit hyperactivity disorder.
Subscribe to our email newsletter
Watson Pharmaceuticals, the recent acquirer of Andrx, is also being named in the lawsuits.
The lawsuits result from an abbreviated new drug application filed by Andrx for generic versions of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg Adderall XR. Andrx provided notice that it would seek to market its generic products before the expiration of the patent in 2018.
The lawsuits allege that all of Andrx’s generic strengths infringe the patents in suit. Pursuant to legislation, there will be a 30-month stay with respect to Andrx’s proposed generic products.
Shire focuses its business on attention deficit, hyperactivity disorder, human genetic therapies and gastrointestinal and renal diseases.